Notícias uniQure NV - QURE | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
uniQure NV (QURE)
uniQure NV (QURE) Notícias

uniQure NV (QURE)

14,20

0,42

(3,05%)

No fechamento: 14 Março 5:00PM

Atrasado por 15 minutos

14,68

0,48

( 3,38% )

Após o horário de negociação: 5:59PM

Atrasado por 15 minutos

Capacite seu portfólio: Discussões em tempo real e ideias de negociação acionáveis.

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

uniQure Announces Pricing of its Public Offering

Form 424B5 - Prospectus [Rule 424(b)(5)]

uniQure Announces Proposed Public Offering

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Pennsylvania Real Estate...

American Funds 2070 Targ...

BNP Paribas Issuance

Amg Systematica Managed ...

New York Mortgage

AVEO Pharmaceuticals

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições